Part of the Hidradenitis Suppurativa Knowledge Library
Hidradenitis Suppurativa Misdiagnosis: Common Diseases Mistaken for HS
IntroductionHidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (Alikhan et al., 2010). Despite its debilitating effects, HS often goes undiagnosed or is misdiagnosed due to its overlapping symptoms with other skin and systemic conditions (Jfri et al., 2019). This misdiagnosis can delay effective treatment, exacerbate symptoms, and lead to emotional and physical complications.
At EliteAyurveda, we specialize in providing accurate diagnosis and holistic care for HS, integrating Ayurvedic principles to address not just the symptoms but the root causes of the condition.
Hidradenitis Suppurativa Misdiagnosis
HS is often misunderstood or overlooked by medical practitioners unfamiliar with its unique characteristics (Vinding et al., 2014). Due to its rarity compared to more common skin conditions, many doctors may fail to recognize it in its early stages.
The painful nodules, abscesses, and sinus tracts characteristic of HS are similar to symptoms seen in other conditions, such as boils, acne, or cysts (Garg et al., 2017). This similarity can lead to incorrect diagnoses and inappropriate treatments.
In its initial stages, HS may appear as isolated lumps or small abscesses, which are easily mistaken for localized infections or folliculitis (Dessauer et al., 2019). Patients themselves may dismiss these symptoms as minor issues, further delaying diagnosis.
When HS progresses to later stages involving sinus tracts and scarring, it may mimic severe dermatological or systemic conditions, complicating diagnosis even further (Sabin et al., 2020).
To improve awareness, it’s important to identify the conditions most frequently misdiagnosed as HS:
Misdiagnosing HS can lead to several complications:
When HS is misdiagnosed, patients are often prescribed treatments that fail to address the condition’s underlying causes. This delays effective care, allowing the disease to progress (Jfri et al., 2019).
Untreated or improperly treated HS can lead to increased lesion size, more frequent flare-ups, and severe scarring (Sabin et al., 2020).
Patients living with undiagnosed or mismanaged HS often experience emotional distress, including anxiety, depression, and social withdrawal, due to the stigma associated with visible skin conditions (Machado et al., 2019).
Chronic HS can result in systemic inflammation, increasing the risk of conditions like metabolic syndrome, arthritis, and secondary infections (Fimmel & Zouboulis, 2020).
At EliteAyurveda, we integrate Ayurvedic principles with modern diagnostics to offer a holistic treatment approach. By focusing on the root causes of HS, we ensure personalized care that targets both the skin and systemic aspects of the disease.
In Ayurveda, HS is linked to imbalances in the Pitta (heat and inflammation) and Kapha (blockages and stagnation) doshas (Lad, 2002). These imbalances lead to the accumulation of toxins (Ama) and systemic inflammation (Pole, 2013).
1. Detoxification (Shodhana):
2. Personalized Herbal Medications:
3. Dietary Adjustments:
4. Lifestyle Modifications:
Patient Profile:
Ayurvedic Treatment Plan:
Outcome:
If you experience recurring, painful skin lesions that do not respond to conventional treatments, it’s essential to seek a second opinion. Misdiagnosis is common, and early intervention can prevent complications (Jfri et al., 2019).
Misdiagnosis of Hidradenitis Suppurativa is not uncommon, but it can have profound effects on a patient’s physical and emotional health. At EliteAyurveda, we specialize in identifying HS accurately and managing it holistically through Ayurvedic principles. By addressing the root causes and incorporating modern insights, we help patients achieve sustained relief and improved quality of life.
Take charge of your health today.📞 Contact us at +91 8884722246🌐 Visit our website: www.eliteayurveda.com
Related-
Know More About Ayurveda Hidradenitis suppurative Treatment.
GET IN TOUCH
Contact us
1.Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. (2014) 90(1062):216–21; quiz 20. 10.1136/postgradmedj-2013-131994 [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. (2016) 232(6):687–91. 10.1159/000453355 [DOI] [PubMed] [Google Scholar]
3.Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. (2015) 73(5 Suppl 1):S4–7. 10.1016/j.jaad.2015.07.052 [DOI] [PubMed] [Google Scholar]
4.Reddy S, Strunk A, Garg A. All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States. J Am Acad Dermatol. (2019) 81(4):937–42. 10.1016/j.jaad.2019.06.016 [DOI] [PubMed] [Google Scholar]
5.Reddy S, Strunk A, Garg A. Comparative overall comorbidity burden among patients with hidradenitis suppurativa. JAMA Dermatol. (2019) 155(7):797–802. 10.1001/jamadermatol.2019.0164 [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Canoui-Poitrine F, Le Thuaut A, Revuz JE, Viallette C, Gabison G, Poli F, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. (2013) 133(6):1506–11. 10.1038/jid.2012.472 [DOI] [PubMed] [Google Scholar]
7.Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. (2013) 133(1):97–103. 10.1038/jid.2012.255 [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Andrade T, Vieira BC, Oliveira AMN, Martins TY, Santiago TM, Martelli ACC. Hidradenitis suppurativa: epidemiological study of cases diagnosed at a dermatological reference center in the city of Bauru, in the Brazilian southeast State of Sao Paulo, between 2005 and 2015. An Bras Dermatol. (2017) 92(2):196–9. 10.1590/abd1806-4841.20175588 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Snyder CL, Chen SX, Porter ML. Obstacles to early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol. (2023) 16:1833–41. 10.2147/CCID.S301794 [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Gill L, Williams M, Hamzavi I. Update on hidradenitis suppurativa: connecting the tracts. F1000Prime Rep. (2014) 6:112. 10.12703/P6-112 [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. (2015) 173(6):1546–9. 10.1111/bjd.14038 [DOI] [PubMed] [Google Scholar]
12.Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project. J Am Acad Dermatol. (2020) 82(2):366–76. 10.1016/j.jaad.2019.06.1301 [DOI] [PubMed] [Google Scholar]
13.Creadore A, Desai S, Li SJ, Lee KJ, Bui AN, Villa-Ruiz C, et al. Insurance acceptance, appointment wait time, and dermatologist access across practice types in the US. JAMA Dermatol. (2021) 157(2):181–8. 10.1001/jamadermatol.2020.5173 [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. (2020) 236(5):421–30. 10.1159/000508787 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. (2014) 150(9):937–44. 10.1001/jamadermatol.2014.691 [DOI] [PubMed] [Google Scholar]
16.Shelby D. Hidradenitis Suppurativa: A Disease Under-Diagnosed and Under-Treated. Myrtle Beach: Skin, Bones, Hearts and Private Parts; (2018). Available online at: https://www.skinbonescme.com/2018/02/01/hidradenitis-suppurativa-disease-underdiagnosed-undertreated/ [Google Scholar]
17.Martorell A, Alfageme Roldán F, Vilarrasa Rull E, Ruiz-Villaverde R, Romaní De Gabriel J, García Martínez F, et al. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol. (2019) 33(11):2137–42. 10.1111/jdv.15710 [DOI] [PubMed] [Google Scholar]
18.Di Cesare A, Rosi E, Amerio P, Prignano F. Clinical and ultrasonographic characterization of hidradenitis suppurativa in female patients: impact of early recognition of the disease. Life. (2023) 13(8):1630. 10.3390/life13081630 [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Mendes-Bastos P, Martorell A, Bettoli V, Matos AP, Muscianisi E, Wortsman X. The use of ultrasound and magnetic resonance imaging in the management of hidradenitis suppurativa: a narrative review. Br J Dermatol. (2023) 188(5):591–600. 10.1093/bjd/ljad028 [DOI] [PubMed] [Google Scholar]
20.Manfredini M, Chello C, Ciardo S, Guida S, Chester J, Lasagni C, et al. Hidradenitis suppurativa: morphologic and vascular study of nodular inflammatory lesions by means of optical coherence tomography. Exp Dermatol. (2022) 31(7):1076–82. 10.1111/exd.14560 [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Gierek M, Bergler-Czop B, Słaboń A, Łabuś W, Ochała-Gierek G. Laser speckle contrast analysis (LASCA): a new device in the diagnosis and monitoring of surgical treatment of hidradenitis suppurativa. Postepy Dermatol Alergol. (2023) 40(2):253–8. 10.5114/ada.2023.126323 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Garg A, Reddy S, Kirby J, Strunk A. Development and validation of HSCAPS-1: a clinical decision support tool for diagnosis of hidradenitis suppurativa over cutaneous abscess. Dermatology. (2021) 237(5):719–26. 10.1159/000511077 [DOI] [PubMed] [Google Scholar]
23.Deodhar A, Rozycki M, Garges C, Shukla O, Arndt T, Grabowsky T, et al. Use of machine learning techniques in the development and refinement of a predictive model for early diagnosis of ankylosing spondylitis. Clin Rheumatol. (2020) 39(4):975–82. 10.1007/s10067-019-04553-x [DOI] [PubMed] [Google Scholar]
24.Doyle OM, Leavitt N, Rigg JA. Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data. Sci Rep. (2020) 10(1):10521. 10.1038/s41598-020-67013-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Kitanishi Y, Fujiwara M, Binkowitz B. Patient journey through cases of depression from claims database using machine learning algorithms. PLoS One. (2021) 16(2):e0247059. 10.1371/journal.pone.0247059 [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Nori VS, Hane CA, Martin DC, Kravetz AD, Sanghavi DM. Identifying incident dementia by applying machine learning to a very large administrative claims dataset. PLoS One. (2019) 14(7):e0203246. 10.1371/journal.pone.0203246 [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Huda A, Castano A, Niyogi A, Schumacher J, Stewart M, Bruno M, et al. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat Commun. (2021) 12(1):2725. 10.1038/s41467-021-22876-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Kim GE, Shlyankevich J, Kimball AB. The validity of the diagnostic code for hidradenitis suppurativa in an electronic database. Br J Dermatol. (2014) 171(2):338–42. 10.1111/bjd.13041 [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Marvel J, Vlahiotis A, Sainski-Nguyen A, Willson T, Kimball A. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. BMJ Open. (2019) 9(9):e030579. 10.1136/bmjopen-2019-030579 [DOI] [PMC free article] [PubMed] [Google Scholar]
Medical disclaimer. This article is for general information and is not a substitute for personalised medical advice. Ayurvedic treatment at EliteAyurveda is individualised following clinical assessment. Do not start, stop or alter any prescribed medication without consulting your treating physician.